In January 2013, the average time from submission to first decision for all original research papers submitted to Circulation Research was 12.2 days. Objective: To investigate the underlying cause in patients with clinical signs resembling MD in whom sequencing of the coding region of VEGFR3 did not reveal any pathogenic variation.
INTRODUCTION
Primary lymphedema (PL) is clinically and genetically heterogeneous. 1 PL is caused by anatomical or functional defects in the lymphatic system, leading to chronic swelling of one or more body parts. To date, mutations in seven genes, CCBE1 (MIM 235510), FOXC2 (MIM 153400), GATA2 (MIM 614038), GJC2 (MIM 613480), KIF11 (MIM 152950), SOX18 (MIM 607823), and VEGFR3 (MIM 153100) have been identified as causative for disorders in which PL is a major feature. Still, there are a substantial number of PL patients where the underlying cause has yet to be identified.
Milroy Disease (MD) is an autosomal dominant, congenital form of PL with reduced penetrance. The edema is usually bilateral, painless and chronic, presenting most often at birth, and predominantly of the dorsum of the feet, but may extend further up the lower limb. Variability of expression has been reported. Other clinical features of MD include prominent veins, hydroceles and abnormal lymphoscintigraphy with functional aplasia. 2 Mutations in VEGFR3 (Vascular Endothelial Growth Factor Receptor 3) are known to be causative for about 70% of MD 3 cases and these have recently been summarised. 4 To date, despite several candidate gene screening efforts, no other genes have been associated with MD or Milroy-like disorders.
METHODS
An expanded Methods section including a detailed clinical description of the whole family is available in the Online Supplement.
RESULTS
We present a multi-generational pedigree in which MD-like lymphedema segregates in a pattern consistent with autosomal dominant inheritance ( Figure 1A ). The index patient (Patient II:4) is a male that on examination revealed moderate lymphedema affecting the left below-knee region, with less severe changes in the right below-knee region ( Figure 1B ). His mother (Patient I:2) had suffered with bilateral below-knee lymphedema since childhood ( Figure 1C ). The proband's sister (Patient II:3) presented with congenital lymphedema of both feet and ankles and had prominent veins around the ankles and dorsum of the feet ( Figure 1D ). Patient II:3 had a son (Patient III:2) with congenital lymphedema and prominent veins of both feet and ankles ( Figure 1D ). His swelling spontaneously improved in the third year of life. The affected family members show variable clinical signs, which is common in MD 2 and are described in greater detail in the Online Supplement.
While the index patient's presentation was suggestive of MD, he was found to be negative for VEGFR3 mutations. Whole exome sequencing was performed and we identified one heterozygous frameshift variant (c.571_572insTT; p.Pro191Leufs*10) in VEGFC (Figure 2A ). The change is predicted to be disease-causing, and co-segregated with the disease status in the rest of the family upon Sanger sequencing (LOD score 2.1).
The four affected adults underwent lymphoscintigraphy which showed reduced uptake with tortuous lymphatic tracts and evidence of re-routing ( Figure 1F ). This contrasts with the lymphoscintigrams seen in MD patients with proven mutations in VEGFR3, which show no uptake within the main lymphatic tracts after 2 hours, suggestive of initial lymphatic vessel dysfunction ( Figure 1G ).
VEGFC codes for one of the ligands of the tyrosine kinase receptor VEGFR3. The c.571_572insTT mutation lies within exon 4, encoding part of the VEGF homology domain of VEGFC, leading to a predicted frameshift from codon 191 and a stop codon ten amino acids further downstream ( Figure 2B ). We analysed stability and secretion of the c.571_572insTT variant (VEGFCinsTT) by Western blotting of lysates and supernatants of 293T cells transiently transfected with wildtype human VEGFC (hVEGFC) and the hVEGFCinsTT variant. In hVEGFC transfected cell lysates and supernatants, we detected bands corresponding in size to the differentially processed isoforms of VEGFC (58kD, 31kD, 21kD and 15kD)( Figure 2C ). In lysates of cells transfected with the hVEGFCinsTT variant, we detected a band of approximately 22kD, the predicted molecular weight of the variant, but did not detect any protein in the supernatant ( Figure 2C ). Thus, while VEGFCinsTT encodes a stable protein in cell lysates, secretion of this mutant variant is strongly impaired as compared to wildtype VEGFC.
To analyze the activity of the c.571_572insTT variant in vivo, we established an assay in zebrafish by over-expressing hVEGFC and hVEGFCinsTT in the floorplate while monitoring expression by an IRES tagRFP cassette. Zebrafish Vegfc shares 57% identity with human VEGFC, and in zebrafish, Vegfc signalling via Vegfr3 is required for venous angiogenic sprouting 5 and the development of the lymphatic system. 6 Simultaneous over-expression of hVEGFC and tagRFP in the floorplate of zebrafish embryos led to excessive vessel sprouting at 56hpf ( Figure 3D ), while overexpression of tagRFP alone had no effect on vessel growth ( Figure 3C ). hVEGFC overexpression promoted hypersprouting of venous and lymphatic vessels, but not of arterial vessels (Online Figure  II) . We used this model for testing pathogenicity of the c.571_572insTT mutation in vivo. In contrast to the expression of hVEGFC, expression of hVEGFCinsTT and tagRFP in the floorplate had no detectable effect ( Figure 3E ), indicating that the mutation significantly reduces, or possibly completely abolishes, the biological activity of the protein.
We also considered the possibility of the mutation resulting in a truncated protein with dominant negative properties. However, expressing the c.571_572insTT allele in the zebrafish floorplate assay did not interfere with normal vasculogenesis or angiogenesis (Figure 3e ), rendering the possibility of a dominant negative effect unlikely. Furthermore, we co-overexpressed hVEGFC and hVEGFCinsTT in the zebrafish floorplate, monitoring levels of hVEGFC and hVEGFCinsTT using IRES tagRFP and IRES mturquoise cassettes, respectively. Co-overexpression led to hypersprouting at a similar level to embryos expressing only hVEGFC in the floorplate (Figure 4) . Note that the two transgenes were expressed in the same cells (Online Figure III) . We conclude that the VEGFC insTT variant does not have dominant negative activity, but most likely leads to a haploinsufficient phenotype.
DISCUSSION
VEGFC belongs to the family of vascular endothelial growth factors (VEGFs), which act as ligands for transmembrane tyrosine kinase receptors of the VEGF-receptor family. The c.571_572insTT variant reported here encodes a truncating mutation predicted to be pathogenic using protein structure prediction and a functional assay. In vitro data suggest that the protein is indeed truncated, stable, but does not get secreted efficiently. In patients, this would be predicted to result in reduced VEGFC protein levels thus leading to mild edema formation. Interestingly, haplo-insufficient Vegfc mice and Chy3 mice (hemizygous for Vegfc) survive to adulthood with paw edema and a hypoplastic dermal lymphatic network 7, 8 and the two mouse models are good representatives of the human phenotype. As we have found no evidence for a dominant negative effect of the protein variant, the human patients are likely to present haplo-insufficient scenarios.
To date, only one VEGFC mutation positive patient, and six affected family members have been identified. Screening of a small selection (n=16) of patients with a similar phenotype did not identify additional mutations in the ligand. Other unknown ligands and ligand-independent signalling via VEGFR3 9 may explain why mutations in VEGFC are only responsible for a small fraction of MDlike cases. It is also possible that proband and his family are genetically protected and can compensate for the presumed loss of VEGFC activity by other factors. Further studies are required to fully elucidate this.
In conclusion, we have identified a VEGFC mutation that causes a Milroy-like primary lymphedema. Our findings demonstrate that mutations in VEGFC can cause a phenotype similar to that found in patients with mutations in the VEGFC receptor, VEGFR3. We propose that VEGFCscreening should be considered in patients presenting with a Milroy-like phenotype but no identifiable VEGFR3 mutation, particularly if the lymphoscintigram demonstrates poor uptake with tortuous lymphatics and re-routing. This is the first report in the literature of a human phenotype associated with a VEGFC mutation. 
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Novelty and Significance
What Is Known?
 Primary lymphoedema is a clinically heterogeneous disease with significant inter-and intrafamilial variation.
 Milroy Disease is an autosomal dominant congenital form of lymphoedema. Only 70% of patients with this disease have mutations in VEGFR3, suggesting genetic heterogeneity.
 VEGFC encodes a key ligand for VEGFR3 and is important in lymphangiogenesis.
What New Information Does This Article Contribute?
 Mutations in VEGFC can lead to a Milroy-like phenotype.
 Mutant VEGFC protein is produced but not secreted, suggesting haploinsufficiency asa likely mechanism.
 Forced expression of wildtype, but not mutant VEGFC in the floorplate of zebrafish embryos lead to hyper-sprouting of venous and lymphatic vessels.
We have identified a cohort of patients with congenital primary lymphoedema resembling Milroy Disease (MD) but without mutations in VEGFR3. Whole exome sequencing identified a frameshift variant in VEGFC in one Milroy-like family, which was predicted to be pathogenic. VEGFC is known to be a ligand for VEGFR3 and control lymphatic sprouting during embryonic development. Using a novel in vivo overexpression assay, we show that wild-type human VEGFC, but not mutant VEGFC, leads to excessive sprouting of venous-lymphatic vessels in zebrafish. This indicates that the VEGFC frame-shift mutation is causal for the Milroy-like phenotype seen in this family. VEGFC screening should therefore be considered in patients with Milroy Disease, particularly in those who do carry a mutation in the VEGFR3 gene. 
Supplement Material and Methods
Family Recruitment
Proband and family were ascertained through the Primary Lymphedema (PL) Clinic at St George's Hospital, London, UK. The study obtained ethical approval (South West London Research Ethics Committee -REC Ref: 05/Q0803/257) and written informed consent was obtained from all participants (n=12). Samples for subsequent VEGFC screening were also obtained through the same clinic.
Case Study
The index patient (Patient II:4 in Figure 1A ) was a male aged 32 years, the eldest child of unrelated Caucasian parents. He presented with congenital lymphedema of the left foot and ankle. During childhood he developed swelling of the right foot and ankle, but to a lesser degree. He had no hydroceles and no past medical history of note. Examination revealed moderate lymphedema affecting the left below-knee region ( Figure 1B ). Skin changes included hyperkeratosis, papillomatosis and fibrosis. Less severe changes were present in the right below-knee region. He had a history of a few episodes of left leg cellulitis.
Lymphoscintigraphy examination, imaged 2 hr after injection of radioactive isotope [technetium 99] into the webspaces between the toes, revealed impaired lymphatic drainage in both lower limbs with only 4.8% of tracer activity reaching the right groin and 0.8% reaching the left groin after two hours (less than 8% of tracer in the inguinal lymph nodes at two hours is considered abnormal). Images showed re-routing of tracer around the foot, ankle and lower legs. Some filling of the main lymphatic tracts is subsequently seen in the region of the knees with faint uptake in these main tracts to the groin. There was a reduction in uptake of tracer within the groin lymph nodes, the left side affected more than the right, in keeping with the severity of his lymphedema ( Figure 1F ). Scan appearances were similar but not typical of those seen in patients with Milroy disease ( Figure 1G ) and very different from a healthy control ( Figure 1E ). The index patient had two children, a son 
Targeted Capture and Massive Parallel Sequencing
Whole exome capture was performed using the SureSelect Target Enrichment System (Agilent). This was followed by sequencing on a HiSeq200 (Illumina) with 100bp paired end reads; summary statistics are provided in Online Table I . Sequence reads were aligned to the reference genome (hg19) using Novoalign (Novocraft Technologies SdnBhd). Duplicate reads, resulting from PCR clonality or optical duplicates, and reads mapping to multiple locations were excluded from downstream analysis. Depth and breadth of sequence coverage were calculated with custom scripts and the BedTools package.
1
Read Mapping and Variant Analysis
Single-nucleotide substitutions and small indel variants were identified (Online Table II ) and quality filtered within the SamTools software package 2 and in-house software tools. 3 Variants were annotated with respect to genes and transcripts with the Annovar tool. 4 Variants were filtered for novelty by comparing them to dbSNP135 and 1000 Genomes SNP calls and to variants identified in 650 control exomes (primarily of European origin), which we sequenced and analysed by the method described above. Initial analysis of our PL exome variant profiles is performed by filtering for a list of genes known to be involved in lymphatic development and maintenance, and a heterozygous frameshift variant in VEGFC was identified.
Confirmation Sequencing
Subsequently, the rest of the family (n=11) was screened for this VEGFC variant using Sanger sequencing. Previously designed primers 5 for VEGFC (NM_005429.2) were used: 4F 5'-aacatagcgtcctgcgtaca-3' and 4R 5'-aaaatacgcttcccactgaa-3'(T A = 57q, 1.5mM Mg ++ ). PCR products were sequenced using BigDye Terminator v3.1 and an ABI3130xla Genetic Analyser. Sequencing traces were visually inspected in Finch TV v1.4 (Geospiza Inc, Seattle, WA, USA). The variant co-segregated with the disease status in the family. A further 7 heterozygous nonsense and indel variants were identified in the exome of the proband, none of which cosegregated with disease in the family (Online Table III ).
Sequencing of all seven VEGFC coding exons and flanking intronic areas (primer sequences and PCR conditions are available upon request) in a small selection of patients with a similar phenotype (n=16 MD VEGFR3 mutation negative cases) did not reveal any VEGFC mutations, deletions or copy number variants. Furthermore, we have not identified additional VEGFC mutations in any of our other PL exomes (n>50, mix of PL phenotypes including MD-like phenotype).
Cloning
The mutant VEGFCinsTT variant (hVEGFCinsTT) was generated by amplifying the coding sequence of full length wildtype human VEGFC (hVEGFC) in a pCS2 vector, according to the QuikChange Site-Directed Mutagenesis protocol (Stratagene) and using the primer pair 5'gaaattacagtgcTTctctctctcaaggccccaaacc3' and 5'ggtttggggccttgagagagagAAgcactgtaatttc3'. An IRES site followed by tagRFP was introduced downstream of the hVEGFC and hVEGFCinsTT in pCS2. For expression of human VEGF-C in the zebrafish floor plate, the hVEGFC IRES tagRFP and hVEGFCinsTT were each cloned into a plasmid containing the sonic hedgehog promoter and a floor plate specific enhancer (Ar-B) 6 flanked by MiniTol2 sites. 7 Diagrams of the constructs are shown in Online Figure I . For certain assays, the IRES tagRFP cassette was replaced by an IRES mturquoise cassette.
Western blot analysis of transiently transfected 293T cells 293T cells were transfected with the pCS2 expression vector coding for hVEGFC or hVEGFCinsTT using X-treme gene 9 (Roche) according to manufacturers' protocol. Three days post transfection conditioned medium was collected and cells were lysed in RIPA/SDS buffer. Conditioned media and cell lysates were mixed with Laemmli buffer and analyzed by Western blotting using VEGFC specific antibodies binding to the N-terminus of the VEGF homology domain (VEGFC isoform 103 antibody, antibodies-online).
Zebrafish assay
All zebrafish strains were maintained in the Hubrecht Institute using standard husbandry conditions. Animal experiments were approved by the Animal Experimentation Committee of the Royal Netherlands Academy of Arts and Sciences (DEC). The transgenic reporter line TG(flt4:yfp), marking blood and lymphatic endothelial cells, was generated from BAC DKEY-58G10, using standard methods 8 , and will be described in detail elsewhere.
Ectopic over-expression in the floorplate was driven by a sonic hedgehog promoter and a floorplate specific activator region 6 and an estimate of the expression of hVEGFC was obtained and monitored by simultaneous expression of tagRFP. Plasmids encoding the hVEGFC or hVEGFCinsTT cDNA and the floorplate specific promoter and enhancer regions flanked by MiniTol2sites, 7 were co-injected at 25 ng/μl together with tol2 transposase mRNA (25 ng/μl) into zebrafish eggs at the 1-2 cell stage. Embryos were selected at 2 dpf for comparable expression of tagRFP and imaged at 56 hpf on a Leica SPE confocal microscope. For certain assays, an estimate of the expression of VEGFC was obtained and monitored by simultaneous expression of mturquoise instead of tagRFP. Due to technical limitations, the expression of mturquoise could not be imaged on this confocal microscope. Thus, mturquoise was imaged separately using a Leica AF7000 microscope. Online Table I 
